波士顿科学Boston Scientific Corporation (BSX) 2014年年度报告「NYSE」.pdf

1、Transforming lives.boston scientific 2014 AnnuAl RepoRtfinAnciAl HiGHliGHts Throughout this Annual Report,unless otherwise noted,all revenue and growth rates represent 2014 growth compared to 2013.Information on or connected to our website(or the website of any third party)referenced in this Annual

2、Report is in addition to and not a part of or incorporated by reference into this Annual Report.1 Operational sales/revenue and growth rates are non-GAAP measures that exclude the impact of sales from divested businesses and changes in foreign currency exchange rates;see reconciliation to GAAP sales

3、/revenue and growth rates on page 8.2 Adjusted operating income excludes certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker considers to be non-recurring and/or non-operational,such as amounts related to goodwill and other intangible as

4、set impairment charges;acquisition and divestiture-,restructuring-,and litigation-related charges and credits;and amortization expense.Icon denotes additional information online at OPERATIONAL SALES BY PRODUCT CATEGORY (Dollars in millions)1 2014 Growth cARdiovAsculAR interventional cardiology$2,092

5、 5%peripheral interventions 861 7%RHytHm mAnAGement cardiac Rhythm management 1,922 2%electrophysiology 228 48%medsuRG endoscopy 1,343 5%urology and Womens Health 542 7%neuromodulation 474 5%$7,462 6%2013ADJUSTED OPERATING MARGIN 20100020003000400050006000700080002014051015202520.2%18.9%2013OPERATIO

6、NAL NET SALES (Dollars in millions)10100020003000400050006000700080002014$7,072+6%0200040006000800010000$7,462 our adjusted earnings per share were$0.84 in 2014,compared to$0.73 in 2013,representing a 15 percent increase year-over-year.4 We reported a GAAp loss of$0.09 per share for both 2014 and 20